Perbandingan Kadar Testosteron dan Lemak Viseral Pasien Sindrom Ovarium Polikistik di Poliklinik Aster RSUP Dr. Hasan Sadikin Bandung Sebelum dan Setelah Pemberian Terapi Metformin
Abstract
Tujuan: Terdapat 50-70% kasus sindrom ovarium polikistik yang berkaitan dengan adanya resistensi insulin. Peran agen sensitisasi insulin seperti metformin diharapkan dapat memperbaiki kondisi lemak dan testosteron bebas yang tinggi sehingga memperbaiki gejala klinis pasien dengan sindrom ovarium polikistik. Penelitian ini bertujuan mengetahui perbedaan indeks androgen bebas (sebagai representasi kadar testosteron) dan lemak viseral pasien sindrom ovarium polikistik sebelum dan sesudah diberi pengobatan metformin.
Metode: Populasi penelitian didapatkan dari data penelitian DLBS (Dexa Laboratories of Biomolecular Sciences) 3233 yaitu 29 kasus wanita sindrom ovarium polikistik yang datang untuk berobat di Klinik Aster RSUP Dr. Hasan Sadikin Bandung periode Januari 2013 - Desember 2017, dengan menggunakan metode experimental design dengan pendekatan one group pretest-posttest design. Pengambilan sampel penelitian dilakukan secara purposing sampling yang diambil secara retrospektif pada data sekunder yang terdapat dalam rekam medik.
Hasil: Didapatkan rata-rata indeks androgen bebas sebelum pemberian terapi metformin 2.67 ± 0.43 dan sesudah pemberian terapi 1.88 ± 0.37. Rata-rata kadar lemak visceral sebelum pemberian terapi metformin 10.27±2.589% dan sesudah pemberian terapi 8.00±1.488%.
Kesimpulan: Sehingga disimpulkan terdapat perbedaan signifikan kadar indeks androgen bebas (p:0.008) dan lemak visceral (p:0,0001) pada pasien sindrom ovarium polikistik sebelum dan sesudah pemberian terapi metformin.
Comparasion of free Androgen Index and Viseral Fat in Polycystic Ovary Syndrome Patients in Aster Polyclinic Dr. Hasan Sadikin Bandung Before and After Giving Metformin Therapy
Abstract
Objective: There are 50-70% of cases of polycystic ovary syndrome associated with insulin resistance. The role of insulin sensitizing agents such as metformin is expected to improve the condition of high fat and free testosteron, thereby improving the clinical symptoms of patients with polycystic ovary syndrome. This study aims to determine differences in free androgen index (represent the value of free testosteron) and visceral fat levels of polycystic ovary syndrome patients before and after being given metformin treatment.
Method: The study population was obtained from DLBS (Dexa Laboratories of Biomolecular Sciences) 3233 research data, namely 29 cases of polycystic ovary syndrome women who came for treatment at the Aster Clinic Dr. Hasan Sadikin Bandung from January 2013 - December 2017, using the experimental design method with the one group pretest-posttest design approach. Sampling was done by purposing sampling taken retrospectively on secondary data contained in the medical record.
Result: The average free androgen index levels were obtained before the administration of metformin therapy 2.67 ± 0.43 and after the administration of therapy 1.88 ± 0.37 Average visceral fat levels before administration of metformin therapy 10.27 ± 2.589% and after administration of 8.00 ± 1,488%.
Conclusion : It was concluded that there were significant differences in free androgen index (p: 0.008) and visceral fat (p: 0.0001) in patients with polycystic ovary syndrome before and after metformin therapy.
Key word: Polycystic ovary syndrome, free androgen index, viseral fat, metformin
Keywords
Full Text:
PDFReferences
Hestiantoro A, Wiweke B, Maidarti Mi, Fernando D, Puspita CG. Sindrom Ovarium Polikistik. In: Hestianto A, Natadisastra M, Wiweko B, Sumapraja K, Harzif A kemal, editors. Current Updates on Polycystic ovary syndrome Endometriosis Adenomyosis. Jakarta: Sagung Seto; 2013. p. 3–69.
Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15.
Mohammad MB, Seghinsara A majdi. Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. Asian Pacific J Cancer Prev. 2017;18(27):17–21.
Schorge JO, Schaffer JI, Halvorson LM, Hoffman BL, Bradshaw KD, Cunningham FG. Williams Gynecology. Schorge JO, Schaffer JI, Halvorson LM, Hoffman BL, Bradshaw KD, Cunningham FG, editors. 2008. 779-806 p.
Sirmans SM, Pate KA. Epidemiology-diagnosis-and-management-of-polycystic-ovary-s. Dove Press J [Internet]. 2014;1–13.
Ding T, Hardiman PJ, Petersen I, Wang F-F, Qu F, Baio G. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget. 2017;8(56):96351–8.
Xita N, Georgiou I, Tsatsoulis A. The genetic basis of polycystic ovary syndrome. Eur J Endocrinol. 2002 Dec;147(6):717–25.
Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. Endocrine. 2006 Aug;30(1):19–26.
DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005 May;83(5):1454–60.
Berek JS. Berek & Novak’s gynecology. 15th ed. Berek JS, Novak E, editors. 2012. 1542-1558 p.
Singh B, Panda S, Nanda R. Effect of Metformin on Hormonal and Biochemical Profile in PCOS Before and After Therapy. Ind J Clin Biochem. 2010;25(February 2006):367–70.
Fauser BCJM, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28–38.e25.
Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG. 2006 Oct;113(10):1203–9.
Karabulut A, Yaylali GF, Demirlenk S, Sevket O, Acun A. Evaluation of body fat distribution in PCOS and its association with carotid atherosclerosis and insulin resistance. Gynecol Endocrinol. 2012 Feb;28(2):111–4.
Wilcox T, Hirshkowitz A. Testosterone and Visceral Fat in Midlife Women: The Study of Women’s Health Across the Nation (SWAN) Fat Patterning Study. NIH Public Access. 2015;85(0 1):1–27.
DOI: http://dx.doi.org/10.24198/obgynia.v4i1.205
Refbacks
- There are currently no refbacks.